TPD & Induced Proximity Summit Leaderboard
  • Monday, June 22, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 74

Author

Pharma Journalist 8887 posts 0 comments

Medera’s Novoheart Teams Up to Develop Mini-Heart Models for Hypoplastic Left Heart Syndrome…

Jun 25, 2025
Medera Inc., a clinical-stage biopharmaceutical company focused on cardiovascular disease therapies, and its pre-clinical subsidiary Novoheart, specializing in human cardiac tissue…
Read More...

Novo Nordisk’s Ozempic Recommended by EU for Peripheral Arterial Disease in Type 2 Diabetes

Jun 24, 2025
Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to update the label of Ozempic…
Read More...

Datroway Approved in U.S. for Advanced EGFR-Mutated Lung Cancer

Jun 24, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Datroway (datopotamab deruxtecan or Dato-DXd) for the treatment of adult patients with locally advanced…
Read More...

argenx Wins EU Approval for VYVGART SC to Treat CIDP

Jun 24, 2025
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the European Commission (EC) approved VYVGART…
Read More...

Harbour BioMed and Otsuka Partner Globally to Develop BCMAxCD3 Bispecific T-Cell Engagers

Jun 24, 2025
Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, announced a global strategic…
Read More...

Archeus Technologies Gets FDA Clearance for ART-101 Prostate Cancer Trial

Jun 23, 2025
Archeus Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting…
Read More...

Health Canada Approves Novartis’ KISQALI for High-Risk Early Breast Cancer

Jun 23, 2025
Health Canada has approved Novartis' KISQALI (ribociclib tablets) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive (HR+),…
Read More...

Advarra Launches AI Council to Boost Innovation in Clinical Trials

Jun 20, 2025
Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on…
Read More...

RyboDyn Joins Lilly Gateway Labs to Advance Immunotherapies Targeting Dark Proteome

Jun 20, 2025
RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an…
Read More...

Yeztugo Becomes First FDA-Approved HIV Prevention with 6-Month Protection

Jun 20, 2025
Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) as a pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1.…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.